Regeneron’s Phase 3 trial of fianlimab plus cemiplimab in first-line unresectable or metastatic melanoma did not meet its primary endpoint. That single sentence just reshuffled the competitive math across one of oncology’s most crowded — and most lucrative — therapeutic spaces.
The failure lands hard because the Phase 2 data had looked genuinely compelling. Across 98 anti–PD-L1-naive patients with advanced melanoma, the fianlimab-cemiplimab combination delivered a 61.2% objective response rate (95% CI, 51%–71%), with a median duration of response that remained unreached at data cutoff, according to results published in Targeted Oncology. An ORR above 60% with durable responses is the kind of number that clears regulatory conversations. It is the kind of number that makes BD teams at rival firms start building defensives. And it is the kind of number that, when Phase 3 fails to replicate it at the primary endpoint level, raises uncomfortable questions about study design, patient selection, and whether the LAG-3 signal in melanoma is narrower than the field assumed.
The street had been watching this readout as a potential multi-billion-dollar catalyst for Regeneron. It will not be that today.
The LAG-3 Calculus Shifts
To understand what this miss means, go back to March 18, 2022 — the day the FDA approved Opdualag (nivolumab plus relatlimab) for adult and pediatric patients 12 years and older with unresectable or metastatic melanoma. That approval validated the LAG-3 mechanism in melanoma and handed Bristol-Myers Squibb a first-mover advantage in the checkpoint combination space. The conventional read at the time was that Opdualag’s lead would be temporary — that Regeneron’s fianlimab data would eventually force a competitive reckoning and compress BMS’s pricing power.
That logic held — until today’s readout changed the timeline entirely. With fianlimab’s Phase 3 stumbling in first-line melanoma, Opdualag’s runway just extended. BMS faces no approved LAG-3 competitor in this indication for the foreseeable future, and the regulatory clock to any fianlimab-based challenge — if Regeneron chooses to pursue one — has reset to zero. The window BMS needs to entrench Opdualag in treatment guidelines, build KOL relationships, and lock in formulary positioning just got wider.
The benchmark Regeneron needed to clear was not modest. The CheckMate-067 trial established that nivolumab plus ipilimumab achieves a 58% ORR in first-line advanced melanoma — and that combination has had years to define the standard of care. Clearing 58% on ORR while also hitting survival endpoints in a registrational trial is a high bar, particularly when the control arm in any contemporary trial benefits from the same rising tide of improved supportive care. The Phase 2 ORR of 61.2% looked differentiated on paper. Phase 3 disagreed.
Who Absorbs the Damage
Regeneron’s portfolio resilience is real — Dupixent generated over $13 billion in 2024 net sales and continues to expand across indications — but fianlimab was supposed to be the asset that demonstrated Regeneron could build an oncology franchise, not just a single immunology blockbuster. That narrative takes a significant hit. The company has already absorbed turbulence: a Phase 3 trial of Dupixent in chronic pruritus of unknown origin missed its primary itch responder endpoint in Study A, according to BioPharma reporting on the company’s recent regulatory and development challenges. A fianlimab failure in melanoma compounds the R&D momentum problem heading into the second half of 2026.
The capital allocation question is now unavoidable. Regeneron spent years building out cemiplimab as an oncology backbone — it holds approvals in cutaneous squamous cell carcinoma, non-small cell lung cancer, and cervical cancer — and fianlimab was the next layer designed to extend that franchise into competitive melanoma territory. Redirecting that R&D investment, whether toward salvage trials in different lines of therapy, alternative indications, or new combination strategies, will require Regeneron’s oncology leadership to make decisions under the worst possible conditions: after a public Phase 3 miss with no immediate replacement asset at a comparable stage.
BMS is the clearest beneficiary. Opdualag’s commercial team woke up this morning with a simpler competitive story to tell oncologists and payers. Merck’s Keytruda (pembrolizumab) monotherapy and combination regimens remain the dominant force in melanoma broadly, but within the LAG-3 subcategory, BMS now has the market to itself for an indeterminate period. Every quarter without a credible fianlimab competitor is a quarter in which Opdualag can deepen its formulary position and generate the real-world outcomes data that eventually becomes the next layer of guideline entrenchment.
What Decision-Makers Should Do Now
If you are a mid-cap immuno-oncology company with a LAG-3 or next-generation checkpoint asset in Phase 1 or Phase 2, this readout is a two-sided signal. The failure raises the bar for mechanism validation — investors and partners will now demand sharper patient-selection biomarkers and more rigorous trial emulation before committing Phase 3 capital to LAG-3 combinations. But it also removes one of the most credible competitive threats from the near-term landscape. A well-differentiated LAG-3 program with a biomarker hypothesis that Regeneron’s design did not test — PD-L1 expression stratification, tumor mutational burden enrichment, specific LAG-3 expression thresholds — could attract partnering interest from companies that still need a melanoma story and no longer fear walking into a Regeneron-dominated market.
The next signal to watch is Regeneron’s formal response: whether the company discloses a pre-specified subgroup analysis that preserves a path to an accelerated approval in a biomarker-selected population, or whether it moves fianlimab into an earlier-line or adjuvant setting where the competitive bar and the regulatory pathway are different. A silence on subgroup data in the coming weeks would suggest the miss was broad-based. A rapid pivot announcement would signal the asset still has commercial life — but in a narrower, lower-revenue indication than the first-line metastatic opportunity that just closed.
References
- GlobeNewswire — “Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma”
- Targeted Oncology — “Fianlimab Combined With Cemiplimab Elicits Durable Responses in Advanced Melanoma”
- AACR — “Immune Checkpoint Therapy Combination Approved for Advanced Melanoma” (Opdualag FDA approval, March 18, 2022)
- Cancer Letter — CheckMate-067: Nivolumab plus Ipilimumab 58% ORR in First-Line Advanced Melanoma
- BioPharma — “Regeneron Climbs Back After a Year of Regulatory and Manufacturing Misery”
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
